David Morris, MD, FACS

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.

David Morris, MD, FACS, discusses overall survival data with apalutamide in prostate cancer.

David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.

David Morris, MD, FACS, discusses the safety profiles and common adverse events related to the androgen receptor inhibitors apalutamide, enzalutamide, and darolutamide for prostate cancer.